Catalent Announces Chief Financial Officer Succession
May 11 2021 - 7:00AM
Business Wire
Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products, today announced the promotion of Thomas
Castellano to serve as the company’s Senior Vice President and
Chief Financial Officer effective June 1, 2021, succeeding Wetteny
Joseph who will be leaving the company to become the Chief
Financial Officer of Zoetis Inc.
“On behalf of the Board, our shareholders, and all of us at
Catalent, we’d like to thank Wetteny for his long and dedicated
service, and we wish him every success in his future endeavors,”
said John Chiminski, Chair and Chief Executive Officer. “We are
delighted to recognize Tom’s continuing contributions and
development as a senior executive at Catalent, and I look forward
to working with him in his new role. Today’s smooth succession
demonstrates the strength of Catalent’s bench and our proactive
planning and executive development efforts.”
Mr. Castellano, 41, currently serves as Catalent’s Global Vice
President of Operational Finance, providing finance partnership on
strategic execution across the company’s business units, and as a
member of Catalent’s Executive Leadership Team. He joined the
company as Director for Financial Planning & Analysis in 2008,
playing an integral role in Catalent’s successful initial public
offering in 2014, and has served in successively senior positions
since then, including as Vice President, Financial Planning &
Analysis and Vice President, Finance, Investor Relations, and
Treasurer. Prior to joining the company, he worked with the capital
markets finance group at Lehman Brothers, holding roles of
increasing responsibility. Mr. Castellano began his career at
Cendant Corporation as part of its financial leadership development
program. He holds a bachelor’s degree in finance and an MBA, both
from Seton Hall University.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell
and gene therapies, and consumer health products. With over 85
years serving the industry, Catalent has proven expertise in
bringing more customer products to market faster, enhancing product
performance and ensuring reliable clinical and commercial product
supply. Catalent employs more than 14,000 people, including
approximately 2,500 scientists, at more than 45 facilities across
four continents and in fiscal year 2020 generated over $3 billion
in annual revenue. Catalent is headquartered in Somerset, N.J. For
more information, please visit www.catalent.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511005307/en/
Media Contacts: Chris Halling +44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns +44 (0) 161 728 5880 richard@nepr.agency
Investors: Paul Surdez +1 (732) 537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Sep 2023 to Sep 2024